First Two Patients Enrolled in Randomized Phase 2, COVID-19 Trial with Leronlimab; Five More Severely Ill COVID-19 Patients Treated Under Emergency IND and Two Patients Have Already Extubated Apr 06, 2020 6:00am EDT
CytoDyn CEO Dr. Pourhassan Appearance on Fox Business Network Rescheduled to April 8 Same Time (11am PT); CytoDyn will Reveal Today the Name of the Hospital and the Physician who Treated 10 Patients During an Interview on Seattle-Affiliate of CBS News which Will Air Between 5-6:30 p.m. PT Apr 03, 2020 1:48pm EDT
CytoDyn Files Request with FDA for Preliminary Meeting for Breakthrough Therapy Designation for Leronlimab in the Treatment of Cancer Apr 03, 2020 6:15am EDT
CytoDyn CEO Dr. Pourhassan to Appear on Fox Business Network Friday, April 3, 2020 at 2:00 pm ET to Discuss Leronlimab Treatment of 10 Severely Ill COVID-19 Patients and Express Appreciation for a Special Hospital, Physician, and Medical Team Who Treated These Patients Apr 03, 2020 6:00am EDT
Treatment with CytoDyn's Leronlimab Indicates Significant Trend Toward Immunological Restoration in Severely Ill COVID-19 Patients Apr 02, 2020 6:00am EDT
CytoDyn Files a Clinical Trial Protocol with the FDA to Treat Severely Ill COVID-19 Patients with Leronlimab where the Primary Endpoint is Mortality Rate at Two Weeks Apr 01, 2020 6:00am EDT
CytoDyn Completes Non-dilutive $15 Million Convertible Note Financing with Conversion Rate at $4.50 Per Share without Warrants Mar 31, 2020 6:15am EDT
FDA Clears CytoDyn’s Phase 2 Randomized Trial to Treat Mild-to-Moderately Ill Coronavirus Patients with Leronlimab; Enrollment to Begin Immediately Mar 31, 2020 6:00am EDT
Three Additional Patients with Severe COVID-19 Treated with Leronlimab in New York Medical Center Bringing the Total to 10 Patients Mar 30, 2020 6:00am EDT
CytoDyn Files FDA-Suggested Modifications to IND and Protocol for Phase 2 Clinical Trial for COVID-19 Patients with Mild to Moderate Indications and a Second Randomized Protocol for All COVID-19 Patients in Severe Condition Will be Filed Next Week per FDA Recommendation Mar 27, 2020 6:15am EDT
